EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of Cytomegalovirus Immunoglobulin with Antiviral Therapy for Cytomegalovirus Infection in Transplant Recipients: A Tertiary Care Single-Center Experience

Reem M Alameer, Bayan Alamro, Khulud Alanazi, Ali Alahmari, Ghadeer Almousa, Abdullah Almohaizeie iD, Hadeel Samarkandi, Reem S Almaghrabi

Viruses · 25.05.2026 · 18 (6) · 599

DOI: 10.3390/v18060599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 25.05.2026. Verfasst von Reem M Alameer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Transplant Infectious Diseases, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Makkah Al Muka…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Antiviral Agents, Transplant Recipients, Cytomegalovirus. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) infection is a major contributor to morbidity and mortality in recipients of hematopoietic stem cell transplant (HSCT), solid organ transplant (SOT), and chimeric antigen receptor T-cell (CAR-T) therapy. While antiviral agents remain the cornerstone of treatment, CMV-specific immunoglobulins (CMVIG) have been utilized as adjunct therapy with variable outcomes. This study aims to evaluate the virological response and tolerability of CMVIG in cases of severe or refractory CMV viremia, with or without CMV disease.

Methods

We conducted a single-center retrospective case series of adult recipients of SOT, allogeneic HSCT, and/or CAR-T cell therapy who developed CMV viremia or disease and received at least one dose of CMVIG between May 2017 and May 2023 at our center. Virological improvement within 14 days of starting CMVIG and tolerability of CMVIG are the primary outcome of this study.

Results

A total of 33 patients were included. Of these, 29 underwent transplantation [SOT: 48.2%, HSCT: 51.7%], and five underwent CAR-T cell therapy (one post-HSCT). High-risk CMV serostatus was present in 12%. CMV viremia was documented in 32 patients (97%), and tissue-invasive disease was present in 11 patients (33.3%). Virological response, was observed in 65.6% of the cohort. The median time to undetectable CMV viral load following CMVIG initiation was 28 days. CMVIG was well-tolerated. All-cause mortality at 90 days remained high (57%).

Conclusion

In this case series, CMVIG demonstrated a virological response rate of 65.6% in patients with severe or refractory CMV infection. While CMVIG was well-tolerated with minimal adverse events, the high mortality rate despite virological response suggests that CMVIG may be insufficient for this critically ill population. Our findings should be interpreted as observational data from a small case series, and prospective controlled trials are needed to establish the true benefit of CMVIG in combination with standard antiviral therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsAntiviral AgentsTransplant RecipientsCytomegalovirusImmunoglobulinsHumansRetrospective StudiesFemaleMiddle AgedMaleAdultHematopoietic Stem Cell TransplantationViremiaTertiary Care CentersTreatment OutcomeOrgan TransplantationAgedImmunoglobulins, Intravenous

Stichwörter der Autor:innen

CMV immunoglobulinCytomegalovirusand chimeric antigen receptor T-cell (CAR-T) therapyhematopoietic stem cell transplantsolid organ transplant

Substanzen

Antiviral AgentsImmunoglobulinscytomegalovirus-specific hyperimmune globulinImmunoglobulins, Intravenous

Autor:innen und Institutionen

  • Section of Transplant Infectious Diseases, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Makkah Al Mukarramah Branch Road, Al Maather, Riyadh 12713, Saudi Arabia.
  • Section of Infectious Diseases, Internal Medicine Department, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
  • Department of Hematology, Stem Cell Transplantation & Cellular Therapy, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
  • Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia.
  • College of Pharmacy, Alfaisal University, Riyadh 11533, Saudi Arabia.

ORCID-Profile: Abdullah Almohaizeie

Zitieren

APA

Alameer, R. M., Alamro, B., Alanazi, K., Alahmari, A., Almousa, G., Almohaizeie, A., Samarkandi, H., & Almaghrabi, R. S. (2026). Use of Cytomegalovirus Immunoglobulin with Antiviral Therapy for Cytomegalovirus Infection in Transplant Recipients: A Tertiary Care Single-Center Experience. Viruses, 18(6), 599. https://doi.org/10.3390/v18060599

Vancouver

Alameer RM, Alamro B, Alanazi K, Alahmari A, Almousa G, Almohaizeie A, et al. Use of Cytomegalovirus Immunoglobulin with Antiviral Therapy for Cytomegalovirus Infection in Transplant Recipients: A Tertiary Care Single-Center Experience. Viruses. 2026;18(6):599. doi:10.3390/v18060599

BibTeX
@article{Alameer2026,
  author = {Alameer, Reem M and Alamro, Bayan and Alanazi, Khulud and Alahmari, Ali and Almousa, Ghadeer and Almohaizeie, Abdullah and Samarkandi, Hadeel and Almaghrabi, Reem S},
  title = {Use of Cytomegalovirus Immunoglobulin with Antiviral Therapy for Cytomegalovirus Infection in Transplant Recipients: A Tertiary Care Single-Center Experience},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {599},
  doi = {10.3390/v18060599}
}
Kostenlos starten →